Comparison of Effects of α-Glucosidase Inhibitors and Glinide Drugs on Endothelial Dysfunction in Diabetic Patients With Coronary Artery Disease

Sawada, Takahiro; Shiotani, Hideyuki; Terashita, Daisuke; Nagasawa, Yoshinori; Kim, Sushi-ku; Koide, Masaaki; Yokoyama, Mitsuhiro

doi:10.1253/circj.cj-13-0918

Cited by 21 publications

(17 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To address the conflicting results described above, Sawada et al compared the effects of a-GI and glinide [31] and showed that reduction of oxidative stress and improvements endothelial function were observed only for patients treated with a-GI. Yamazaki et al reported that glinide treatment was more beneficial than SU for decreasing daily glucose variability; comparisons were also made to determine the effects of glinide and SU treatments on oxidative stress [32].…”

Section: Discussionmentioning

confidence: 99%

Improvements of ambient hyperglycemia and glycemic variability are associated with reduction in oxidative stress for patients with type 2 diabetes

Ohara

Nagaike

Goto

et al. 2018

Diabetes Research and Clinical Practice

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Improvements of ambient hyperglycemia and glycemic variability are associated with reduction in oxidative stress for patients with type 2 diabetes

Ohara

Nagaike

Goto

et al. 2018

Diabetes Research and Clinical Practice

View full text Add to dashboard Cite

show abstract

“…Maruyama et al demonstrated that the TG/HDL-C ratio was associated with LDL particle size [17]. Previous reports revealed that a high TG/HDL-C ratio was associated with cardiovascular disease and all-cause death among patients with DM or metabolic syndrome [17, 32, 33] and the amelioration of this abnormality was associated with improvements in endothelial dysfunction [34]. Thus, high TG/HDL-C ratio was regarded as an important residual cardiovascular risk and a therapeutic target for decreasing cardiovascular events in DM patients.…”

Section: Discussionmentioning

confidence: 99%

Effects of 6-month eicosapentaenoic acid treatment on postprandial hyperglycemia, hyperlipidemia, insulin secretion ability, and concomitant endothelial dysfunction among newly-diagnosed impaired glucose metabolism patients with coronary artery disease. An open label, single blinded, prospective randomized controlled trial

Sawada

Tsubata

Hashimoto³

et al. 2016

Cardiovasc Diabetol

Self Cite

View full text Add to dashboard Cite

BackgroundRecent experimental studies have revealed that n-3 fatty acids, such as eicosapentaenoic acid (EPA) regulate postprandial insulin secretion, and correct postprandial glucose and lipid abnormalities. However, the effects of 6-month EPA treatment on postprandial hyperglycemia and hyperlipidemia, insulin secretion, and concomitant endothelial dysfunction remain unknown in patients with impaired glucose metabolism (IGM) and coronary artery disease (CAD).Methods and resultsWe randomized 107 newly diagnosed IGM patients with CAD to receive either 1800 mg/day of EPA (EPA group, n = 53) or no EPA (n = 54). Cookie meal testing (carbohydrates: 75 g, fat: 28.5 g) and endothelial function testing using fasting-state flow-mediated dilatation (FMD) were performed before and after 6 months of treatment. The primary outcome of this study was changes in postprandial glycemic and triglyceridemic control and secondary outcomes were improvement of insulin secretion and endothelial dysfunction. After 6 months, the EPA group exhibited significant improvements in EPA/arachidonic acid, fasting triglyceride (TG), and high-density lipoprotein cholesterol (HDL-C). The EPA group also exhibited significant decreases in the incremental TG peak, area under the curve (AUC) for postprandial TG, incremental glucose peak, AUC for postprandial glucose, and improvements in glycometabolism categorization. No significant changes were observed for hemoglobin A1c and fasting plasma glucose levels. The EPA group exhibited a significant increase in AUC-immune reactive insulin/AUC-plasma glucose ratio (which indicates postprandial insulin secretory ability) and significant improvements in FMD. Multiple regression analysis revealed that decreases in the TG/HDL-C ratio and incremental TG peak were independent predictors of FMD improvement in the EPA group.ConclusionsEPA corrected postprandial hypertriglyceridemia, hyperglycemia and insulin secretion ability. This amelioration of several metabolic abnormalities was accompanied by recovery of concomitant endothelial dysfunction in newly diagnosed IGM patients with CAD.Clinical Trial Registration UMIN Registry number: UMIN000011265 (https://www.upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&action=brows&type=summary&recptno=R000013200&language=E)Electronic supplementary materialThe online version of this article (doi:10.1186/s12933-016-0437-y) contains supplementary material, which is available to authorized users.

show abstract

“…On the other hand, glinides suppress postprandial glucose excursion through increasing early phase insulin secretion after meal ingestion. Recently, Sawada et al have reported a comparison of the effects on oxidative stress and endothelial function between a glinide and an AGI [87]. In this study, a total of 104 patients with T2DM were randomly assigned to treatment with miglitol or nateglinide.…”

Section: Discussionmentioning

confidence: 99%

Glycemic Variability and Oxidative Stress: A Link between Diabetes and Cardiovascular Disease?

Saisho

2014

IJMS

145

134

View full text Add to dashboard Cite

Diabetes is associated with a two to three-fold increase in risk of cardiovascular disease. However, intensive glucose-lowering therapy aiming at reducing HbA1c to a near-normal level failed to suppress cardiovascular events in recent randomized controlled trials. HbA1c reflects average glucose level rather than glycemic variability. In in vivo and in vitro studies, glycemic variability has been shown to be associated with greater reactive oxygen species production and vascular damage, compared to chronic hyperglycemia. These findings suggest that management of glycemic variability may reduce cardiovascular disease in patients with diabetes; however, clinical studies have shown conflicting results. This review summarizes the current knowledge on glycemic variability and oxidative stress, and discusses the clinical implications.

show abstract

Comparison of Effects of α-Glucosidase Inhibitors and Glinide Drugs on Endothelial Dysfunction in Diabetic Patients With Coronary Artery Disease

Cited by 21 publications

References 23 publications

Improvements of ambient hyperglycemia and glycemic variability are associated with reduction in oxidative stress for patients with type 2 diabetes

Improvements of ambient hyperglycemia and glycemic variability are associated with reduction in oxidative stress for patients with type 2 diabetes

Glycemic Variability and Oxidative Stress: A Link between Diabetes and Cardiovascular Disease?

Contact Info

Product

Resources

About